Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C.

Pegylated interferon and Ribavirin are the treatment backbone for chronic hepatitis C and may favour the development of psychiatric symptoms. These adverse events may reduce treatment adherence and are a risk factor for its failure. The recent experts’ recommendations of European Association for the Study of the Liver, suggest monitoring psychiatric manifestations on a regular basis during the antiviral treatment but the frequency of psychiatric controls sometimes might be insufficient. We present a particular case of a young woman without psychiatric history, who developed different mood and behavioural disturbances during antiviral therapy, that required an intensive psychiatric monitoring and supportive psychotherapy.